How Cosentyx Works for Psoriasis
Cosentyx (secukinumab) is an IL-17A inhibitor that targets inflammation in moderate-to-severe plaque psoriasis. It reduces skin plaques and symptoms like itching and scaling, often showing results in weeks.[1]
Other Biologic IL-17 Inhibitors Like Cosentyx
These drugs block the same IL-17 pathway, offering similar efficacy for plaque psoriasis:
- Taltz (ixekizumab): Weekly injections initially, then monthly. Matches Cosentyx in clearing 90% of skin (PASI 90) for many patients.[1][2]
- Bimzelx (bimekizumab): Targets both IL-17A and IL-17F. Approved for psoriasis in 2023; studies show faster skin clearance than Cosentyx in head-to-head trials.[1][3]
TNF Inhibitors as an Alternative Class
TNF blockers reduce broader inflammation and treat psoriasis plus psoriatic arthritis:
- Humira (adalimumab): Every-other-week injections. Long track record but higher infection risk than IL-17 drugs.[1]
- Enbrel (etanercept): Weekly self-injections. Effective for skin and joints.[1]
- Simponi (golimumab) and Cimzia (certolizumab pegol): Less common for psoriasis alone but used with arthritis.[1]
IL-23 Inhibitors for Targeted Psoriasis Control
These block an upstream inflammation signal, often with fewer doses:
- Tremfya (guselkumab): Every 8 weeks after loading doses. High clearance rates, good for long-term use.[1][2]
- Skyrizi (risankizumab): Every 12 weeks. Strong data on sustained remission.[1]
- Ilumya (tildrakizumab): Every 12 weeks. Focuses on skin psoriasis.[1]
IL-12/23 Inhibitor Option
- Stelara (ustekinumab): Every 12 weeks after induction. Dual blockade; effective but slightly less potent for severe cases than newer IL-17/23 drugs.[1][2]
Non-Biologic Alternatives When Biologics Aren't First-Line
For milder cases or before biologics:
- Otezla (apremilast): Daily oral PDE4 inhibitor. Improves plaques without injections but slower onset.[1]
- Topicals like Vtama (tapinarof) or Zoryve (roflumilast cream): Non-steroidal creams for mild-to-moderate psoriasis.[1]
- Methotrexate or cyclosporine: Older systemic orals for short-term control.[1]
How These Compare in Efficacy and Use
IL-17 inhibitors like Taltz and Bimzelx often edge out others for rapid, deep skin clearance (90-100% improvement). IL-23 drugs excel in maintenance with less frequent dosing. TNFs suit patients with comorbidities like IBD. Choice depends on arthritis presence, infection history, and insurance—biologics cost $5,000-$7,000/month before rebates.[2][3]
| Drug Class | Examples | Dosing Frequency | Key Edge Over Cosentyx |
|------------|----------|------------------|------------------------|
| IL-17 | Taltz, Bimzelx | Monthly/every 8 weeks | Bimzelx: Dual IL-17 block, quicker results |
| IL-23 | Tremfya, Skyrizi | Every 8-12 weeks | Fewer shots, sustained clearance |
| TNF | Humira, Enbrel | Weekly/biweekly | Joint-focused, cheaper generics emerging |
| IL-12/23 | Stelara | Every 12 weeks | Broad approval (including Crohn's) |
Common Side Effects Across Options
All biologics raise infection risk (upper respiratory, yeast). IL-17 drugs like Cosentyx link to more candida infections; monitor with antifungals. TNFs have higher TB reactivation odds. Screen for hepatitis before starting.[1][2]
When to Switch from Cosentyx
If inadequate response after 3-6 months, dermatologists rotate to IL-23 (e.g., Skyrizi) or IL-17 alternatives. Biosimilars for Humira/Enbrel lower costs.[3]
Sources
[1] Drugs.com - Psoriasis Treatments
[2] DrugPatentWatch.com - Cosentyx
[3] FDA.gov - Psoriasis Medications